In mice with the APOE4 gene, a key protein that maintains electrical balance in brain cells is reduced, and when this protein is blocked experimentally, neurons become overactive and fire abnormally, indicating that loss of this protein may help trigger seizures.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether reduced hippocampal Na+/K+-ATPase expression or activity is consistently observed in human APOE4 carriers with epilepsy or Alzheimer’s disease compared to non-carriers.
A systematic review and meta-analysis of all human postmortem, PET, and CSF studies measuring Na+/K+-ATPase α1 expression or activity in APOE4 carriers with and without seizures, using standardized assays and controlling for age, dementia stage, and antiepileptic drugs.
Whether enhancing Na+/K+-ATPase activity reduces seizure frequency in APOE4 carriers with epilepsy.
A double-blind, placebo-controlled trial of 100 APOE4 homozygous adults with focal epilepsy, randomized to a Na+/K+-ATPase activator (e.g., digoxin at subtoxic doses) or placebo for 24 weeks, with primary outcome being reduction in seizure frequency and secondary outcomes including EEG biomarkers and hippocampal ATP via MRS.
Whether APOE4 carriers with declining hippocampal Na+/K+-ATPase activity on MRS show progressive increases in subclinical seizure burden.
A prospective cohort of 300 APOE4 carriers aged 60–75, followed for 5 years with annual MRS to measure hippocampal Na+/K+-ATPase activity (via sodium imaging), EEG monitoring for subclinical seizures, and cognitive testing, adjusting for Aβ and tau burden.
Whether APOE4 carriers who died of seizures have lower hippocampal Na+/K+-ATPase α1 expression than those who died of non-seizure causes.
A case-control study comparing 40 APOE4 carriers who died of status epilepticus with 40 APOE4 carriers who died of non-seizure causes, matched for age and dementia stage, measuring Na+/K+-ATPase α1 protein levels via immunoblot in postmortem hippocampal tissue.
Whether APOE4 carriers with epilepsy have lower hippocampal sodium pump activity on MRS than non-carriers with similar seizure burden.
A cross-sectional study of 100 individuals with epilepsy (50 APOE4 carriers, 50 non-carriers), matched for seizure frequency and duration, undergoing sodium MRI to quantify hippocampal sodium concentration as a proxy for Na+/K+-ATPase activity.